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Abstract
NAFLD is diagnosed, when the liver fat exceeds more than 5% of liver weight. Inside 
of hepatocytes, these fats are stored in cytosolic lipid droplets. The lipid droplets can 
be formed from a bud, vesicles of the lipid bilayer, which lines at a vicinity of the 
endoplasmic reticulum (ER). On the surface of droplets, there are several structural/
functional proteins such as lipid droplet proteins, lipogenic enzymes, and lipases. 
Interestingly, the lipid droplet proteins seem to have great impact on a development of 
NAFLD. Some proteins can interact with transcriptional factors such as SREBP1c and 
PPAR-alpha/gamma, and some proteins strongly impact a mitochondrial structure. As 
a result, the lipid droplet proteins highly influence lipid handling and fatty acid oxida-
tion in hepatocytes. This chapter will elucidate our recent understanding of the role 
of each lipid droplet protein in fatty liver formation and in hepatic insulin resistance. 
Existing information on genetically modified animals as well as on human NAFLD 
was reviewed on Perilipin families, CIDE proteins, Seipin, and PNPLAs. Finally, the 
chapter will discuss how the lipid droplet proteins could potentially lead/protect from 
hepatic insulin resistance via abnormal accumulation of ceramides and diacylglycerols, 
autophagy, ER stress, and oxidative stress.
Keywords: perilipin, CIDE proteins, insulin sensitivity, mitochondrial oxidation, 
autophagy, ER stress
1. Introduction
Liver can store a certain amount of excess glucose as a form of glycogen. A part of the stored 
glycogen can then be retransformed into glucose (so-called gluconeogenesis) during a fast-
ing condition to leave the liver. Contrary to the glucose, an excess lipid is not normally 
stored in the liver. However, in a pathological case, excess lipid storage can be observed 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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in hepatocytes, which is called hepatic steatosis. Hepatic steatosis could be diagnosed in 
different grades according to histological observation (Grade 1: 5–33% lipid invasion in 
hepatocytes, Grade 2: 33–66%, and Grade 3: >66%). Up to 90% of obese patients could have 
the hepatic steatosis, and the presence is linked to several metabolic dysfunctions such as 
insulin resistance, oxidative stress, endoplasmic reticulum (ER) stress, and mitochondrial 
dysfunctions [1–3]. As a result, hepatic steatosis often leads to abnormal gluconeogenesis, 
which is a typical phenotype of type 2 diabetes. To better prevent such metabolic dysfunc-
tions, scientists have been actively investigating mechanisms by which hepatic lipids impact 
metabolic functions.
2. Lipid droplet structure
When excess fat is present in a liver, these fats are stored intracellularly in cytosolic 
lipid droplet compartment. Today, an origin of a lipid droplet biosynthesis has not been 
understood completely. Walther and Farese suggested different models of the lipid drop-
let biosynthesis [4]. Most accepted lipid droplet biosynthesis model is that triglyceride 
(TG) accumulated at the ER membranes forms a bud, a vesicle of the lipid bilayer [5]. 
On ER membranes, phospholipids are added onto the surface of growing lipid drop-
lets. Secondary, lipid droplets could increase their size via lipid droplet fusion. Finally, a 
matured lipid droplet is formed consisting TG and cholesterol esters in a core, coated by 
a membrane monolayer of phospholipids and sphingomyelin (Figure 1A). On the surface 
and/or vicinity of droplets, there are several structural/functional proteins such as lipid 
Figure 1. Lipid droplet formation. (A) Formation of nascent lipid droplet (LD) with lipid droplet proteins (LDPs), 
(B) lipid droplet biology.
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droplet proteins, lipogenic enzymes, and lipases (Figure 1B). Enzymes required for lipid 
droplet synthesis are also located in the ER. This strategic enzyme location helps to form, 
stabilize, and degrade lipid droplets when necessary. Hydrolysis of lipid is highly regu-
lated by different enzymes such as adipose triglyceride lipase (ATGL), hormone-sensitive 
lipase (HSL), and monoglyceride lipase (MGL). ATGL is responsible for the hydrolysis of 
triglyceride, followed by HSL, which cleaves one molecule of fatty acid from diacylglyc-
erol, and finally hydrolysis is completed by MGL. In hepatocytes, ATGL interacts both 
lipid droplet protein, perilipin 5 (PLIN5) and comparative gene identification-58 (CGI-58). 
When ATGL interacts with PLIN5, this decreases lipolysis; however, if ATGL interacts with 
CGI-58, this increases lipolysis [6]. Therefore, lipid droplet proteins play a key role regulat-
ing a fate of cellular lipid storage (Table 1).
LD protein Expression cites Observed functions Reported interactions with 
other genes/proteins
PLIN1 (perilipin A) WAT, cardiac muscle 
liposarcoma, BAT
LD stability, control of 
hormone-induced lipolysis
ATGL, CGI58, [97, 98], 
SREBP1c [19], CIDEC [15]
PLIN2 (ADRP, 
adipophilin)
Liver, WAT, mammary gland, 
macrophages, sebocytes, 
ubiquitous expression
LD stability, adipocytes 
differentiation, VLDL 
lipidation
PPAR alpha, gamma [21, 
99, 100], delta [101]
hepatic von Hippel-
Lindau protein [102]
PLIN3 (TIP47) Ubiquitous expression, 
skeletal muscle, neutrophils, 
sebocytes
LD stability, PGE2 production, intracellular trafficking
Mannose-6-phosphate 
receptor [9]
PLIN4 (S3-12) WAT, skeletal muscle LD stability, adipocytes 
differentiation
PLIN5 [32]
PLIN5 (OXPAT, 
LSDP5, MLDP)
Skeletal muscle, BAT, heart, 
liver, beta-cells
LD stability, fat oxidation, 
mitochondrial recruitment
PPARalpha [60], delta 
[103], CIG58, ATGL [6], 
ABHD5 [104]
PLPNA3 
(Adiponutrin)
WAT, liver, skeletal muscle, 
pancreas
Triglyceride and retinyl 
palmitate esterase activity
SREBP1c [105]
PLPNA2 (ATGL) Adipose tissue Lipolysis SIRT1 [106], PLIN5 [6], 
PLIN1 [33, 97]
CIDEA Adipose tissue, liver Lipogenesis SREBP1c [41, 42]
CIDEB Adipose tissue Contributes to lipogenesis, 
lipidation of VLDL, hepatitis 
virus assembly
HCV NS58 protein [107]
CIDEC (FSP27) Adipose tissue, liver LD stability, LF fusion, lipid 
transfer
PPAR alpha, gamma 
[42, 45]
SEIPIN (BCSL) Adipose tissue, liver, brain, 
testis
Maturation of LD, lipolysis
Table 1. Lipid droplet proteins.
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3. Lipid droplet protein families
Lipid droplet proteins were discovered in the 1990s in phospholipid monolayer of lipid drop-
let [7–9]. At that time, each lipid droplet proteins had a different nomenclature. In 2010, it was 
suggested to uniform their names as the “perilipin family protein: PAT protein” [10]. PAT 
was named after the three proteins: PLIN1 (Perilipin), PLIN2 (Adipose differentiation-related 
protein; ADRP), and PLIN3 (Tail-interacting protein of 47 kDa; TIP47). All PLIN families con-
tain a conserved domain called PAT domain [11] with an exception of PLIN4 that only con-
tains long 11-mer repeat motifs [12]. The expression of these proteins and their functions are 
slightly different, and their exact roles for each cell type have not been yet completely under-
stood. Interestingly, their expression depends on a size of lipid droplets (small lipid droplets: 
PLIN3, PLIN4, PLIN5; medium lipid droplets: PLIN2; and large lipid droplet: PLIN1).
3.1. PLIN1
PLIN1 was one of the first lipid droplet protein identified in adipocytes [13, 14], and its 
expression is mainly observed in matured adipocytes. During a differentiation of premature 
adipocytes, PLIN2 plays a major role to lipidate small lipid droplets. Once lipid droplet gains 
enough size, PLIN1 replaces PLIN2 to stabilize large lipid-rich lipid droplets and helps to 
mature adipocytes. PLIN1 also interacts with cell-death-inducing DNA-fragmentation-factor 
45-like effector (CIDE)-C for a lipid droplets fusion process [15]. Among different reported 
functions of PLIN1 in adipocytes, the most well-characterized role of PLIN1 is a control of 
lipolysis. PLIN1 co-localizes with ATGL and CGI-58 on a surface of lipid droplets at a basal 
condition. Upon a lipolytic stimulation, PLIN1 is phosphorylated and CGI-58 is released and 
activates ATGL for a lipolysis. In hepatocytes, PLIN1 is not expressed in normal healthy liver, 
but its expression is observed in steatotic hepatocytes [16–18]. During a formation of hepatic 
steatosis, the expression of PLIN1 is synchronized with sterol regulatory element-binding 
protein (SREBP)-1c, a key regulator of de novo lipogenesis [19]. As a result, both genes could 
strongly contribute to accelerate the pathogenesis of hepatic steatosis [20].
3.2. PLIN2
PLIN2 was originally named as adipose differentiation-related protein due to its high expres-
sion during an adipocyte differentiation [8]. PLIN2 is ubiquitously expressed and its expres-
sion in the liver is high among other lipid droplet proteins [21]. Chronic alcohol consumption 
stimulates de novo lipogenesis and induces hepatic steatosis together with an upregulation of 
PLIN2 [22]. Hepatocellular ballooning and oxidative injury were also observed under such 
condition [18]. Magne et al. observed in human NAFLD patients that PLIN2 polymorphism 
(ser1Pro) was linked to a decreased VLDL levels [23].
A recent study demonstrated that the PLIN2 and PLIN3 double-knockout in hepatocytes 
induced insulin resistance [24]. In addition, the overexpression of PLIN2 in rat skeletal muscle 
resulted in an accumulation of TG in muscle without insulin resistance [25]. However, general 
deletion of PLIN2 in mice also showed a protective role against hepatic steatosis and insulin 
resistance (discussed in a later paragraph, Table 2). The exact impacts of PLIN2 modification 
on insulin resistance have not yet been fully elucidated.
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3.3. PLIN3
PLIN3 was originally named tail-interacting protein of 47 kDa and ubiquitously expressed 
among tissues. PLIN3 is localized at the cytosol and lipid droplet [9, 26]. It is also implicated 
in intracellular trafficking of lysosomal enzymes [9]. Four-helix bundle in PLIN3 has been 
LD proteins Up or downregulation Outcomes
PLIN1 Downregulation
KO mice [61]
KO mice [62]
Body fat↓, fat oxidation↑
Lipolysis↑, cardiac steatosis↑, cardiac 
hypertrophy
PLIN2 Downregulation
ASO [63, 64]
KO—alcohol diet [66]
KO—high fat diet [65]
Liver specific KO—methionine-choline deficient 
diet [95]
Lep (ob/ob)/Plin2 double KO mice [108]
KO–high fat diet [109]
Hepatic steatosis↓ (ceramide-, DAG↓), IR ↓
Hepatic steatosis↓ (ceramide↓), IR ↓, glucose 
tolerance-
Hepatic steatosis↓, body fat↓, adipose 
inflammation↓
Hepatic steatosis↓, hepatic inflammation↓, 
fibrosis↓
VLDL secretion ↑
Hepatic steatosis ↓, IR↓ (liver, muscle)
Hepatic steatosis ↓VLDL -
PLIN3 Downregulation
ASO [67]
Hepatic steatosis ↓
IR↓
PLIN4 Downregulation
KO [32]
Cardiac steatosis↓
PLIN5 Downregulation
KO [38]
KO [40]
Upregulation
Adenovirus [68]
Lack of lipid droplet in heart, ROS↑, heart mal 
function,
Hepatic steatosis ↓, mitochondrial oxidative 
capacity↑, lipotoxic injury
Hepatic steatosis ↑
IR-
PLPNA3 Downregulation
KO [55, 56]
Upregulation
G allele knock-in Ref. [57]
Hepatic steatosis -
Hepatic steatosis ↑
PLPNA2 Downregulation
KO [69]
Liver-specific KO [70]
Steatosis in different organs↑, IR↓
Hepatic steatosis ↑ (DAG↓), IR -
CIDEC Downregulation
KO [47, 110]
KO in ob/ob by shRNA [46]
ASO [111]
Upregulation
Adenovirus [46]
Hepatic steatosis ↓, IR↓
Hepatic steatosis ↓, IR↓
Hepatic steatosis ↓, body fat↓, IR↓
Hepatic steatosis↑
SEIPIN Downregulation
Adipose-specific KO [112]
KO [49]
Upregulation
Transgenic mice overexpressing a short isoform of 
human BSCL2 in adipose [113]
Hepatic steatosis↑, IR↑, adipocyte hypertrophy 
and progressive lipodystrophy
Hepatic steatosis↑, IR↑
Hepatic steatosis↑, IR↑, white adipose tissue ↓, 
lipolysis ↑
Abbreviations: KO; knockout, ASO; antisense oligonucleotide, IR; insulin resistance.
Table 2. Experimental modification of lipid droplet protein and the effect on steatosis.
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suggested to contribute to fatty acid binding and lipid droplet recruitment [9]. PLIN2 and 
PLIN3 share similar functions, and both proteins cannot bind CGI-58 and, therefore, influ-
ence lipolysis [27]. Co-expression of PLIN2 and PLIN3 has been reported in many tissues; 
however, a distinct role of PLIN3 has not been clearly identified. Interestingly, PLIN3 expres-
sion was also observed in stellate cells in the liver [17]. Lipopolysaccharide treatment also 
predominantly stimulated PLIN3 expression in HL-60-derived neutrophils [28]. Knockdown 
of PLIN3 via siRNA decreased a lipid droplet formation as well as PGE2 secretion. This obser-vation was unique to PLIN3, and PLIN2 was not detected under such conditions. This implies 
that PLIN3 might be implicated in a lipid droplet formation related to conditions with cel-
lular stresses.
Another unique observation to PLIN3 was that mice lacking mTORC2 (mammalian target 
of rapamycin complex) activity in skeletal muscle showed increased fat mass and PLIN3 
[29]. This was due to an increased AMPK activity. mTORC plays an important role in insu-
lin signaling. However, the implication of PLIN3 in insulin resistance has not yet been 
addressed.
3.4. PLIN4
PLIN4 was originally called S3–12 and is the only PAT protein that does not contain the PAT 
domain. Its molecular weight is three times higher than other PAT proteins. The protein has 
been shown to present at cytosol and lipid droplets [30]. Its expression was induced dur-
ing adipogenesis [31]. PLIN4-KO mice present no phenotypic changes in adipose tissues, 
whereas TG content in heart tissues was significantly reduced [32]. PLIN5 expression was 
also decreased under such condition. Given close location of PLIN4 and PLIN5 in chromo-
some 19 in human, it was suggested a potential transcriptional interference between two 
genes. PLIN4 remains the least studied PAT protein, and further investigations are required 
to understand PLIN4 roles in lipid droplet physiology.
3.5. PLIN5
PLIN5 was discovered by different researchers simultaneously and named as myocardial 
lipid droplet protein (MDLP), OXPAT, or lipid storage droplet protein 5 (LSDP5) [33, 34]. This 
was due to a high expression of PLIN5 in heart and other oxidative tissues such as skeletal 
muscle and liver. PLIN5 expression is also reported in pancreatic beta cells and hepatic stel-
late cells [35, 36]. A unique feature with PLIN5 is that mitochondria are physically recruited 
to lipid droplets expressing high PLIN5 (Figure 2) [37, 38]. Its expression is regulated by 
PPAR-alpha, and most importantly, PLIN5 plays roles in regulating cellular fat oxidation. 
PLIN5 stabilizes lipid droplets by sequestrating fatty acids, and because PLIN5 can recruit 
mitochondria to lipid droplet surface, it facilitates to release fatty acids to mitochondria for 
the oxidation [39]. Given its gatekeeper roles on the lipid oxidation, it has been suggested that 
PLIN5 could protect cardiac myocytes and hepatocytes from oxidative stress [38, 40]. PLIN5 
leads several modifications on the lipid metabolism as well as insulin sensitivity, and details 
are discussed in a separate paragraph.
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3.6. CIDE proteins
Cell-death-inducing DNA fragmentation-factor 45-like effector (CIDE) proteins have also 
been found on a lipid droplet surface. CIDEA expression is controlled by SREBP-1c and found 
in a fatty liver [41, 42]. CIDEB is constitutively expressed in a liver and plays a role in VLDL 
production [43, 44]. Interestingly, it has been reported that CIDEB and PLIN2 exert opposite 
functions for a control of VLDL lipidation [44]. CIDEC, is also named as fat-specific protein 
27 (FSP27), found as a cofactor of PLIN1 for lipid droplet fusion in adipocytes [15]. CIDEC 
is regulated by PPAR-alpha/gamma [42, 45]. Like CIDEA, hepatic CIDEC was induced in 
leptin-deficient ob/ob mice. It has also been demonstrated that CIDEC overexpression induces 
steatosis, whereas knockdown of CIDEC alleviates hepatic fat accumulation in ob/ob mice 
lacking hepatic PPARγ [46]. Effect of CIDEC on mitochondrial activity and insulin sensitivity 
is an active research field of today [15, 47, 48]. Toy et al. demonstrated that white adipocytes 
from CIDEC KO mice had accelerated mitochondrial activities and increased proteins and 
size, leading to brown adipocyte characteristics.
3.7. SEIPIN
SEIPIN is highly expressed in brain, testis, and adipose tissue. Mutations in SEIPIN are known 
as Berardinelli-Seip congenital lipodystrophy (BSCL), a rare recessive disorder characterized by 
near absence of adipose tissue accompanied by a severe insulin resistance [49]. Several studies 
convincingly demonstrated that SEIPIN plays a crucial role in adipogenesis, lipid droplet homeo-
stasis and lipolysis. It is also well known that human BSCL patients and mice lacking SEIPIN 
develop diabetes and severe hepatic steatosis. Interestingly, our previous studies demonstrated 
that SEIPIN expression seems to be dependent on lipid droplet size (Figure 3), and the low 
SEIPIN expresser had an impaired gluconeogenesis in NAFLD patients (personal observation).
Figure 2. Electron microscopy image of hepatocyte overexpressing PLIN5. When PLIN5 is overexpressed, mitochondria 
(closed triangle) is highly recruited toward lipid droplets (LD). N: nucleus.
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3.8. PNPLA3 and PNPLA2
Patatin-like phospholipase domain-containing protein 3 (PNPLA3), also called adiponutrin, 
was consistently associated with NAFLD in GWAS observations [50, 51]. The single nucleo-
tide polymorphism (SNP) in PNPLA3 was identified as a major determinant of hepatic fat 
content from exome-wide association studies. This is the rs738409 C > G SNP encoding for 
the isoleucine to methionine substitution [50]. PNPLA3 is expressed in the retina, hepatic 
stellate cells, and hepatocytes and localized in the endoplasmic reticulum and at a surface 
of lipid droplets. A mechanism by which PNPLA3 leads the hepatic steatosis phenotype has 
not been clearly understood. PNPLA3 has a triglyceride and retinylpalmitate esterase activity 
[52–54], suggesting a possible link to hepatic fat accumulation. However, PNPLA3 knockout 
mice did not develop hepatic steatosis [55, 56]. Mice having Pnpla3i148m knock-in recently 
showed increased hepatic steatosis [57]. The role of PNPLA3 in the development of NAFLD 
still remains elusive.
PNPLA2 is known as adipose triglyceride transfer protein (ATGL) and is expressed on lipid 
droplet surface at a basal condition. Its activity is strongly influenced by PLINs [25]. As shown 
in Figure 1, ATGL is the first enzyme hydrolyzing neutral lipids.
4. Expression of lipid droplet proteins in human NAFLD
Lipid droplet proteins are highly expressed in human NAFLD. PLIN1, PLIN2, and PLIN3 were 
upregulated in NAFLD [18, 58, 59]. And the distribution of PLINs seems to depend on the lipid 
droplet size [17, 18]. PLIN2 was also observed in stellate cells [18, 59]. We have compared the 
expression of different lipid droplet proteins in human NAFLD. The steatosis was judged by a 
histological assessment showing four different grades (S0 < S1 < S2 < S3). Despite a similar BMI 
among different groups, the gene expression of lipid droplet proteins increased depending on 
the degree of steatosis (Figure 4A). When compared the livers from patients with or without type 
2 diabetes who had a similar degree of hepatic steatosis (S3), the expressions of lipid droplet pro-
teins were significantly lower in diabetic patients than in nondiabetic individuals (Figure 4B). 
This result implies possible link between lipid droplet proteins and hepatic insulin signaling.
Figure 3. Liver histology from NAFLD patients.
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5. Experimental modification of lipid droplet proteins and TG 
accumulation in hepatocytes
It has been shown that modifications on the lipid droplet proteins have striking impacts on 
lipid droplet biology. Hepatic cell line AML-12 is used to study the effect of downregulation 
of SEIPIN gene. Downregulation of the gene markedly altered lipid droplets size distribu-
tions and increased smaller droplets size, suggesting a default in lipid droplet maturation 
(Figure 5). When PLIN5 was knocked down in hepatocytes, the TG content dramatically 
Figure 4. Expression of lipid droplet proteins in human NAFLD. NAFLD patients were separated into 5 groups 
depending on their degree of fatty liver. Gene expression of lipid droplets genes were analysed and compared among 
groups. (A) NALFD non diabetic, (B) Comparison of S3 NAFLD patients with or without type 2 diabetes.
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decreased due to accelerated lipolysis and beta-oxidation [60]. PPAR-alpha was required 
for the PLIN5-induced beta-oxidation. On the contrary, the overexpression of PLIN5 leads 
a significant increase in cellular TG. Therefore, modifications on lipid droplets proteins 
govern intracellular TG content in hepatocytes, although the mechanisms and phenotypes 
(lipid droplet size and/or localization) might be depending on a type of lipid droplet proteins 
involved.
6. Experimental modification of lipid droplet proteins in mice
Table 2 displays animals with genetic modifications in lipid droplet proteins and their effect 
on steatosis and metabolism (Table 2). PLIN1 KO mice present reduced body fat as well as fat 
oxidation judged by respiratory quotient [61]. Another research group also studied the PLIN1 
KO mice and found increased lipolysis and cardiac hypertrophy [62]. PLIN2 null mice stud-
ied by different scientific groups consistently demonstrated a protection against diet-induced 
obesity, fatty liver, and alcohol-induced fatty accompanied by an improved insulin sensitivity 
[63–66]. Similar results were obtained in mice treated by PLIN2 antisense oligonucleotide, 
demonstrating improved insulin sensitivity [64]. PLIN3 downregulation was studied by using 
antisense oligonucleotide (ASO) in C57BL/6 J mice fed high fat diet. The reduction in PLIN3 
significantly decreased hepatic fat content and improved glucose tolerance as well as insulin 
sensitivity in liver, adipose, and skeletal muscle [67]. Chen et al. generated PLIN4 KO mice 
[32], which showed no major modification in body weight and fat mass. Interestingly, only 
cardiac TG content was significantly reduced. The KO mice did not alter any gene expression 
involved in glucose and lipid metabolism. PLIN5 KO mice also developed cardiac dysfunc-
tion. The PLIN5 KO animal displayed reduced hepatic steatosis with increased mitochondrial 
proliferation, lipotoxic injury in the hepatocytes [40]. Interestingly, overexpression of PLIN5 
by use of adenovirus technology demonstrated a development of severe hepatic steatosis 
without a sign of hepatic insulin resistance [68].
Although a strong link between PNPLA3 and hepatic steatosis has been demonstrated 
in GWAS studies [50], absence of PNPLA3 gene did not influence TG hydrolysis, nor did 
Figure 5. Lipid droplet morphology when SEIPIN was downregulated. Downregulation of SEIPIN by siRNA resulted 
in a fractionation of lipid droplets.
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hepatic steatosis [55, 56]. One of a pioneer study on the lipid droplet biology and insulin 
resistance was the PNPLA2/ATGL KO mice published in 2006 [69]. Mice with global ATGL 
deletion induced TG accumulation in all tissues [69]. Surprisingly, despite the severe ste-
atosis, the mice exhibit enhanced glucose tolerance and insulin sensitivity. Later on, Wu 
et al. studied the effect of liver-specific deletion of ATGL [70]. The liver-specific KO mice 
progressively developed a severe form of hepatic steatosis; however, the hepatic DAG con-
tent was 50-fold lower and had comparable plasma glucose, TG, and cholesterol levels to 
those of controls.
CIDEC/FSP27 downregulation was studied in Fsp27−/− and ob/ob × Fsp27−/− mice [46, 47], 
demonstrating decreased hepatic steatosis and insulin resistance. These animals are resistant 
to diet-induced obesity, dyslipidemia. Deletion of SEIPIN, as seen in BSCL patients, leads to 
severe form of hepatic steatosis accompanied by insulin resistance [49].
7. NAFLD and insulin resistance, implication of lipid droplet 
proteins
It has been widely accepted that increased TG content in ectopic organs, especially in the liver 
and skeletal muscle, induces insulin resistance [71–73]. Despite strong evidences demonstrat-
ing the link, there are also a few studies to show that hepatic steatosis can be dissociated from 
Figure 6. Different events leading hepatic insulin resistance in NAFLD. In human NAFLD, increased diacylglycerols 
(DAG) and ceramides are often observed. Under such conditions, autophagy is frequently decreased, leading to a 
disturbed lipid handling as well as increased ER stress and oxidative stress. These factors are known to induce insulin 
resistance.
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insulin resistance such as liver-specific microsomal TG transfer protein (MTP) knockout mice 
[74]. While it is not physiological context at all, it may help to understand the contribution of 
each gene to the development of hepatic steatosis and insulin resistance at a molecular level. 
In a steatotic liver from the MTP knockout mice, we had identified upregulations of differ-
ent lipid droplet proteins such as PLIN5, PLIN2, and SEIPIN. We then hypothesized that the 
upregulation of these genes was not deleterious in terms of hepatic insulin sensitivity. Indeed, 
the overexpression of these lipid droplet proteins always induced TG accumulation in hepa-
tocytes; however, none of these in vitro models developed apparent insulin resistance. If true, 
what mechanisms possibly explain the development of hepatic insulin resistance in NAFLD? 
Different theories are briefly introduced below (Figures 6 and 7).
8. Ceramide/Diacylglycerol theory
In a steatotic liver, different lipid species are accumulated such as diacylglycerol (DAG) and 
ceramide. It was postulated that the accumulation of DAG and/or ceramide induced insulin resis-
tance [75]. However, some of the models of NAFLD present increased hepatic DAG and ceramide 
without insulin resistance. Interestingly, a recent study demonstrated that the abnormal compart-
mentalization of these lipid intermediates, rather than total lipid content, is what might truly inter-
fere with the insulin sensitivity [76]. This might support some inconsistent results from various 
mouse models studied by modulating PLINs (Table 2). DAG induces PKC epsilon translocation 
to the plasma membrane, inhibiting the intracellular kinase domain of the insulin receptor [77, 
78]. In the case of PLIN5 overexpressed liver that was dissociated from hepatic insulin resistance, 
we did not observe the PKC epsilon translocation to the plasma membrane despite significant 
increase in DAG (personal observation). Accumulation of ceramides in the plasma membrane has 
also been demonstrated to disturb insulin signaling [79], and we have only observed significant 
increase in some of ceramides. As the PLIN-induced hepatic steatosis might depend on the type 
Figure 7. Dysregulated factors during steatosis and NASH development. Hepatic steatosis has many dysregulation in 
lipid metabolism, leading to insulin resistance. As a result of accelerated cellular damages due to oxidative stress and ER 
stress, inflammation is installed and NASH development starts.
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of PLIN proteins, each phenotype of hepatic steatosis needs to be finely studied. Therefore, the 
link between DAG/ceramide and hepatic insulin resistance in NAFLD requires more scientific 
investigations on each specific PLIN protein modification.
9. Autophagy theory
Selective autophagy process for a degradation of intracellular lipids is called lipophagy. 
The lipophagy is an additional mechanism that contributes to lipid droplet breakdown, and 
PLIN2 has been shown to play a role in this process [80, 81]. Autophagy is also involved in 
delivering fatty acids to lipid droplets for a lipolysis and mitochondrial oxidation [82, 83]. 
Inhibition of autophagy has been shown to accelerate lipid accumulation and impair beta-oxi-
dation in the liver [84, 85]. Interestingly, atg7 inhibition via shRNA in a mouse liver resulted 
in an impairment of autophagy system together with an impaired insulin signaling and an 
induced ER stress [85]. These effects were completely reversed when a downstream target 
atg5 was blocked. This strongly supports an idea that autophagy plays one of a key role in 
insulin signaling pathway. How the lipophagy and lipid droplet proteins are involved in the 
insulin resistance are still open questions.
10. ER stress theory
Hepatic ER deals with redox regulation, glucose deprivation, protein synthesis, VLDL 
assembly and secretion, and cholesterol biosynthesis. It has been suggested that ER stress 
is implicated in insulin resistance, inflammation, and lipotoxicity, which are frequently 
observed in NAFLD patients [86]. Recently, Akoumi et al. tested a hypothesis that palmi-
tate might induce ER stress by disturbing lipid droplet formation in cytosol and lead to an 
abnormal accumulation of lipid in an ER compartment. They found in cardiomyoblast cell 
line that palmitate-induced ER stress was associated with an abnormal storage of DAGs 
located in the ER. Concomitantly, significant degradation of PLIN2 but not PLIN3 or PLIN5 
was observed, suggesting a potential scenario of PLIN2 as a protector/regulator of ER stress. 
Pharmacological ER stress also demonstrated a role of PLIN2 in ER stress-induced lipogen-
esis [87]. Author suggested that the presence (or induction) of PLIN2 during the ER stress 
might protect hepatocytes by storing lipids in a cytosolic compartment. It was a very tenta-
tive hypothesis; however, it was not supported at least in Saccharomyces cerevisiae that an 
absence of lipid droplet formation did not affect cell viability during ER stress [88]. There 
are still many remaining questions to be answered in the field of ER stress and the role of 
lipid droplet proteins. Their implication on metabolic disease such as NAFLD is one of a key 
aspect to be further investigated.
11. Oxidative stress theory
Reactive oxygen species (ROS) is produced in a highly regulated manner in multiple organ-
elles such as the ER and mitochondria. ROS is produced as a result of oxidative protein 
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folding and mitochondrial respiration. NAFLD, especially NASH (nonalcoholic steatohep-
atitis), has been strongly linked with the biomarkers of oxidative stress [89, 90]. In a case 
of NAFLD development, beta-oxidation can be abnormally stimulated due to an excess 
fat accumulation, which surcharges mitochondrial system for the oxidation. As a result, 
abnormal ROS production at complex I of the mitochondrial electron-transport chain is 
induced, leading to the mitochondrial oxidative damage. Under such condition, the redox 
imbalance, lower antioxidant potential, and an enhanced free-radical activity lead to a sig-
nificant reduction in systemic antioxidant capacity of plasma [91]. These conditions are 
indeed considered as a trigger of “second hit,” which then induces NASH. Cytochrome 
P450 E12 (CYP2E1), a member of the cytochrome P450 mixed-function oxidase system, has 
been found as a marker of NASH, which distinguishes NASH from hepatic steatosis [92]. 
The induction of liver microsomal CYP2E1 contributes as a major free-radical source that 
aggravates oxidative stress in NASH. In addition to ROS production, cytokine is produced 
progressing a fatty liver to NASH. A depletion of n-3 long-chain polyunsaturated fatty 
acids (LCPUFA) was also found in NAFLD/NASH. n-3 LCPUFA has been shown to highly 
influence signaling pathway in a liver and contributes to NAFLD development [93, 94]. The 
n-3 LCPUFA downregulates sterol regulatory element-binding protein-1 (SRBBP-1), there-
fore inhibiting de novo lipogenesis. It could also act as a ligand activators of PPAR-alpha, 
therefore stimulating fatty acid oxidation. The decreased n-3 LCPUFA and increased ratio 
of n-6/n-3 LCPUFA were reported in NAFLD/NASH patients. These conditions acceler-
ate high oxidative stress and hepatocellular injury. Interestingly, Fujii et al. demonstrated 
in NAFLD/NASH patients that PLIN2 seemed preferentially expressed in droplets of bal-
looned hepatocytes. The presence of PLIN2-positive ballooned hepatocytes was indeed 
correlated with inflammation [18]. Indeed, liver-specific knockout of PLIN2 in mice had 
reduced hepatic inflammation [95]. The role of PLIN2 on hepatic inflammation in NAFLD/
NASH needs further investigation.
As indicated previously, PLIN5 has strong interactions with mitochondrial functions. Zheng 
et al. studied myocardium from PLIN5-deficient mice and found that the ROS production 
and malondialdehyde levels, a marker for oxidative stress, were significantly increased [96]. 
In this model, the phosphorylation of PI3K and Akt, which was induced by ischemia/reperfu-
sion injury, was greatly reduced by PLIN5 deletion in the myocardium. It remains an open 
question whether the PLIN5 may have an impact on NASH development by interfering with 
the ROS production.
12. Conclusion
Research on lipid droplet proteins and lipid droplet biology has gained strong insights dur-
ing the last decades. Most of the lipid droplet proteins are induced in NAFLD and required 
for a normal adipogenesis. Given specific expression patterns and roles of lipid droplet 
proteins, the phenotypes lead by experimental modifications of the lipid droplets proteins 
displayed diverse patterns. Further research is required to clarify their roles in NAFLD, spe-
cially by focusing on interactions of different lipid droplet proteins and other functional 
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proteins, lipid droplet localization, interaction with mitochondria as well as fatty acid com-
positions in the droplets. Their roles in mitochondrial physiology are a particular importance 
to understand how lipid droplet protein could influence hepatic energy metabolism and 
insulin signaling.
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